Zur Rose Group completed a capital increase from authorized capital and set the placement price of CHF 287 per new share. A total of 740,823 new shares were sold in an accelerated bookbuilding to institutional investors. Accordingly, Zur Rose raised gross proceeds of CHF 213 million. Jefferies and Bank of America acted as joint global coordinators and joint bookrunners.
Zur Rose Group intends to use the gross proceeds from the capital increase to fund an accelerated roll out of its e-prescription solutions (eRx) and European growth initiatives to broaden its customer base through organic expansion as well as potential acquisitions, to invest in platform and ecosystem partnerships and to fund the acquisition of TeleClinic, as well as for general corporate purposes.